Markets
markets
Claire Yubin Oh & J. Edward Moreno

Novo Nordisk's slide continues after CEO warns of “unprecedented pricing pressure” as outlook overshadows Q4 results

Novo Nordisk’s shares are tumbling further in premarket trading on Wednesday after CEO Mike Doustdar warned that the Danish pharma giant will face “unprecedented” price pressures in 2026, addressing the company’s annual sales forecast which showed a decline in revenue.

“Our 2026 guidance reflects a year of unprecedented pricing pressure,” said Doustdar on a call with journalists, adding in an interview with CNBC that people should expect that US pricing “goes down before it comes back up,” as headwinds from lower US Wegovy pricing emain.

On Tuesday, NVO shares fell double-digits after it forecast that sales and operating profit for 2026 will both decline by between 5% and 13% — analysts were expecting very modest growth in each.

In its 2025 annual report, released on Wednesday morning, the company detailed the disappointing guidance, citing “lower realised prices, including the MFN (“Most Favoured Nations”) agreement in the US and the loss of exclusivity for the semaglutide molecule in certain markets in International Operations.” Novo also added that “positive impacts related to US gross-to-net sales adjustments during 2025 are not anticipated to reoccur.”

Across its actual Q4 results, things were a little rosier: sales and diluted EPS figures for Q4 2025 came in at $12.3 billion and $0.94, respectively, slightly beating analyst consensus estimates in both cases by 0.9% and 1.4% (forecasts compiled by Bloomberg).

Meanwhile, Eli Lilly reported quarterly earnings results and posted 2026 guidance on Wednesday that crushed Wall Street estimates. Indeed, although Novo was first to the GLP-1 market, Lilly is proving fierce competition, having surpassed the Danish giant’s sales by Q2 of last year. The Mounjaro maker’s earnings on Wednesday showed that the gap is only getting wider.

Just as Novo launched a new oral GLP-1 for weight loss in January — and early signs show uptake is strong — Lilly also has a weight loss pill expected to come to market later this year. Novo is also facing patent expiry for semaglutide, the active ingredient in Ozempic and Wegovy, starting this year in major markets like Canada, India and China.

More Markets

See all Markets
Claire Yubin Oh
34m
Uber drops after Q1 profit guidance underwhelms

The company’s Q4 results were solid enough, with bookings marginally ahead of expectations, and adjusted EBITDA in-line.

Uber
J. Edward Moreno
1h
Eli Lilly crushes Q4 estimates, gives cheery 2026 guidance

The company reported earnings results on Wednesday.

Mounjaro injections
markets
Hyunsoo Rim

Lumentum jumps on earnings beat and strong guidance

Lumentum rose about 9% in pre-market trading on Wednesday after the optical and photonics company reported better-than-expected quarterly earnings and guidance.

For the quarter ended December, revenue rose 65% year-on-year to a record $665.5 million, topping Wall Street's estimate of $652.5 million, per Bloomberg. Adjusted earnings per share came in at $1.67, also crushing the $1.42 expected. Looking ahead, Lumentum projected March-quarter revenue of $780 million to $830 million, well above analyst estimates for $745 million.

Lumentum sells optical and photonics components that power telecom networks and cloud data centers, with its customers ranging from equipment makers like Cisco and Ciena to hyperscalers such as Microsoft and Google, which are ramping up AI-heavy data center builds. The company also supplies lasers used in consumer electronics manufacturing, including for Apple.

On the earnings call, management said the order backlog for Optical Circuit Switches (OCS) — a high-margin product used by hyperscalers to build AI clusters — has now surged past $400 million.

markets
Luke Kawa

Nvidia poised to invest $20 billion in OpenAI, per report

Nvidia is close to investing $20 billion in OpenAI’s funding round, per Bloomberg, citing people familiar with the matter.

That would make its OpenAI stake more than the market value of chip designer’s entire portfolio of publicly traded stocks (a little over $15 billion, assuming no changes since their most recent filings).

Media reports have suggested that Amazon and SoftBank would be contributing even more to this oft-discussed funding round, in which the Sam Altman-led venture is aiming to raise $100 billion.

It’s a fairly happy ending after the two sides traded barbs in the press over the past few days, with the Wall Street Journal reporting that Nvidia CEO Jensen Huang had privately questioned the “lack of discipline” in the ChatGPT maker’s business approach, while sources told Reuters that OpenAI was “unsatisfied” by the performance of Nvidia’s AI chips and seeking alternatives.

Luke Kawa
16h
Super Micro crushes estimates for Q2, offers strong guidance

The AI server company just released its fiscal Q2 results.

Super Micro Server

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.
©2026 Sherwood Media, LLC